Prevail Therapeutics Provides PR001 Program Update
09 janv. 2020 16h05 HE
|
Prevail Therapeutics
PR001 Administered to International Type 2 Gaucher Disease Patient Via Compassionate Use Pathway Company Advancing its Phase 1/2 Clinical Trial for the Treatment of Neuronopathic Gaucher Disease and...
Prevail Therapeutics Announces IND Active for PR001 for Treatment of Neuronopathic Gaucher Disease
26 déc. 2019 08h30 HE
|
Prevail Therapeutics
NEW YORK, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or the “Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
Prevail Therapeutics Announces FDA Orphan Drug Designation Granted to PR006 for the Treatment of Patients with Frontotemporal Dementia with a GRN Mutation
16 déc. 2019 16h05 HE
|
Prevail Therapeutics
NEW YORK, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Announces Appointment of Morgan Sheng, Ph.D., to Board of Directors
18 nov. 2019 09h00 HE
|
Prevail Therapeutics
NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...
Prevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights
12 nov. 2019 09h30 HE
|
Prevail Therapeutics
Opened Enrollment of PROPEL Phase 1/2 Trial of PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations PR001 for Neuronopathic Gaucher Disease and PR006 for Frontotemporal Dementia with GRN...
Prevail Therapeutics to Participate in Upcoming November Conferences
06 nov. 2019 16h05 HE
|
Prevail Therapeutics
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases
08 oct. 2019 02h00 HE
|
Prevail Therapeutics
Strategic collaboration focuses on baculovirus/Sf9 expression system for Prevail's pipeline of novel AAV9-based gene therapy programs for patients with neurodegenerative diseases Companies to...
Prevail Therapeutics to Present at Upcoming October Conferences
01 oct. 2019 16h05 HE
|
Prevail Therapeutics
NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
Prevail Therapeutics Announces Addition to Russell 2000®, 3000® and Microcap® Indexes
19 sept. 2019 16h05 HE
|
Prevail Therapeutics
NEW YORK, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...
Prevail Therapeutics Provides Program Update on PR001 in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease
10 sept. 2019 16h05 HE
|
Prevail Therapeutics
NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (NASDAQ: PRVL), a biotechnology company developing AAV-based gene therapies for patients with neurodegenerative disorders,...